A Phase 2 interventional study of RSVPreF3 formulation 3 and RSVPreF3 formulation 2 in Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline. Completed at 8 sites in 3 countries. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-21.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline — 1 open to participants now, 5 under way, 3 of them phase 3. Respiratory Syncytial Virus Infections · GlaxoSmithKline.
Among the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline, this one is the 23rd largest by enrollment, is one of 6 that started in 2019, is one of 9 in phase 2, and was the 14th registered.
306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.
Browse Respiratory Syncytial Virus Infections studies →1 of the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline is open now, in 2 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States, Australia
Ages 18–80 · Healthy volunteers
By country, each count listing its studies:
Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 45 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 13 · Phase 3 21
First in 2013; this study’s year is marked. 6 started in 2019.
This study's enrollment of 509 is above the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.
Median enrollment 642 across the 40 interventional studies. Of the 33 that completed or were terminated, 30 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
1 of the studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07092865GlaxoSmithKlineA Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant | 2027-01-12 |
Add it to your calendar (.ics) → With an account.
Among the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, ability of GSK Biologicals' investigational RSV maternal vaccine (RSVPreF3) to generate an immune response and the degree to which the vaccine can cause side effects, when administered alone and in combination with Boostrix vaccine in healthy non-pregnant women 18-45 years of age. Two dose levels of RSVPreF3 and 2 Boostrix [Diphtheria, Tetanus and acellular Pertussis (dTpa) vaccine] formulations (US and ex-US) will be evaluated. A 2nd dose of RSVPreF3 will be administered in an extension of the study to assess the durability of the immune response after the first dose vaccination, and to assess the safety and immunogenicity following a second dose vaccination of the RSVPreF3 maternal vaccine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Primary study
Female subjects of may be enrolled in the study, if the subject:
Extension study
All subjects must satisfy ALL the following criteria:
Female subjects of childbearing potential are eligible for the extension, if the subject:
Exclusion Criteria:
Primary study
Medical conditions
Prior/Concomitant therapy
Prior/Concurrent clinical study experience • Concurrently participating in another clinical study, at any time during the study, in which the subject has been/will be exposed to an investigational/a non-investigational vaccine/product;
Other exclusions
Extension study
Medical conditions
Prior/Concomitant therapy
Prior/Concurrent clinical study experience
Other exclusions
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects received one dose of 120 μg RSVPreF3 formulation 3 vaccine and either one dose of 300 μg or 500 μg dTpa (Boostrix) vaccine on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received a second dose of 120 μg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end.
Biological: RSVPreF3 formulation 3 · Biological: Boostrix-ex-US · Biological: Boostrix-US
Subjects received one dose of 120 μg RSVPreF3 formulation 3 vaccine and one dose of Placebo on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received a second dose of 120 μg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end.
Biological: RSVPreF3 formulation 3 · Drug: Placebo
Subjects received one dose of 60 μg RSVPreF3 formulation 2 vaccine and either one dose of 300 μg or 500 μg dTpa vaccine on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received one dose of 120 μg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end.
Biological: RSVPreF3 formulation 3 · Biological: RSVPreF3 formulation 2 · Biological: Boostrix-ex-US · Biological: Boostrix-US
Subjects received one dose of 60 μg RSVPreF3 formulation 2 vaccine and one dose of Placebo on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received one dose of 120 μg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end.
Biological: RSVPreF3 formulation 3 · Biological: RSVPreF3 formulation 2 · Drug: Placebo
Subjects received one dose of Placebo and either one dose of 300 μg or 500 μg dTpa vaccine on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received one dose of 120 μg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end.
Biological: RSVPreF3 formulation 3 · Biological: Boostrix-ex-US · Biological: Boostrix-US · Drug: Placebo
One dose of RSVPreF3 formulation 3 vaccine administered intramuscularly in the left or in the non-dominant arm.
One dose of RSVPreF3 formulation 2 vaccine administered intramuscularly in the left arm.
One dose of the dTpa (Ex-US formulation) vaccine administered intramuscularly in the right arm.
One dose of the dTpa vaccine (US formulation) administered intramuscularly in the right arm.
One dose of placebo (NaCl solution) administered intramuscularly in either the left or the right arm.
Percentage of Subjects With Any Solicited Local Adverse Event (AEs) [Primary Study]
Assessed solicited local AEs are: erythema, pain and swelling. Any = occurrence of the adverse event regardless of intensity grade. Any erythema and swelling = adverse event reported with a surface diameter greater than 0 millimeters. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3.
Time frame: From Day 1 to Day 8
Percentage of Subjects With Any Solicited General AEs [Primary Study]
Assessed solicited general AEs are: fatigue, gastrointestinal symptoms, headache and fever (body temperature ≥ 38 degree celcius/100.4 degree Farenhit). Any = occurrence of the adverse event regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3.
Time frame: From Day 1 to Day 8
Percentage of Subjects With Any Unsolicited AEs [Primary Study]
An unsolicited AE is any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is to be reported as an unsolicited AE. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3.
Time frame: From Day 1 to Day 31
Number of Subjects With Any SAEs [Primary Study]
A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. Any is defined as any occurrence of SAE regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3.
Time frame: From Day 1 to Day 31
Percentage of Subjects With Any Solicited Local AEs [Extension Study]
Assessed solicited local AEs are: erythema, pain and swelling. Any = occurrence of the adverse event regardless of intensity grade. Any erythema and swelling = adverse event reported with a surface diameter greater than 0 millimeters. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies.The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3.
Time frame: From the Day of 2nd vaccination to Day 8 post 2nd vaccination
Percentage of Subjects Any Solicited General AEs [Extension Period]
Assessed solicited general AEs are: fatigue, gastrointestinal symptoms, headache and fever(body temperature ≥ 38 degree celcius/100.4 degree Farenhit). Any = occurrence of the adverse event regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3.
Time frame: From the Day of 2nd vaccination to Day 8 post 2nd vaccination
Percentage of Subjects With Any Unsolicited AEs [Extension Period]
An unsolicited AE is any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is to be reported as an unsolicited AE. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3.
Time frame: From the Day of 2nd vaccination to Day 31 post 2nd vaccination
Number of Subjects With Any SAEs [Extension Period]
A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. Any is defined as any occurrence of SAE regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3.
Time frame: From the Day of 2nd vaccination to Day 31 post 2nd vaccination
RSV A Neutralizing Antibody Geometric Mean Titers (GMTs) at Screening [Primary Study]
Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60 (Estimated Dilution 60). The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3.
Time frame: At Screening (Day -7 to Day 1)
RSV A Neutralizing Antibody GMTs at Day 8 [Primary Study]
Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3.
Time frame: At Day 8
RSV A Neutralizing Antibody GMTs at Day 31 [Primary Study]
Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3.
Time frame: At Day 31
RSV PreF3 IgG Antibody Geometric Mean Concentration (GMCs) at Screening [Primary Study]
Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by Enzyme-linked immunosorbent assay (ELISA ). The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3.
Time frame: At Screening (Day -7 to Day 1)
RSV PreF3 IgG GMCs at Day 8 [Primary Study]
Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by Enzyme-linked immunosorbent assay (ELISA). The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3.
Time frame: At Day 8
RSV PreF3 IgG GMCs at Day 31 [Primary Study]
Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by Enzyme-linked immunosorbent assay (ELISA). Analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3.
Time frame: At Day 31
Percentage of Subjects With Any Solicited Local Adverse Event (AEs) by Each Boostrix Formulation [Primary Study]
Assessed solicited local AEs are: erythema, pain and swelling. Any = occurrence of the adverse event regardless of intensity grade. Any erythema and swelling = adverse event reported with a surface diameter greater than 0 millimeters. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the safety response to RSVPreF3.
Time frame: From Day 1 to Day 8
Percentage of Subjects With Any Solicited General AEs by Each Boostrix Formulation [Primary Study]
Assessed solicited general AEs are: fatigue, gastrointestinal symptoms, headache and fever(body temperature ≥ 38 degree celcius/100.4 degree Farenhit). Any = occurrence of the adverse event regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the safety response to RSVPreF3.
Time frame: From Day 1 to Day 8
Percentage of Subjects With Any Unsolicited AEs by Each Boostrix Formulation [Primary Study]
An unsolicited AE is any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is to be reported as an unsolicited AE. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the safety response to RSVPreF3.
Time frame: From Day 1 to Day 31
Number of Subjects With Any SAEs by Each Boostrix Formulation [Primary Study]
A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. Any is defined as any occurrence of SAE regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the safety response to RSVPreF3.
Time frame: From Day 1 to Day 31
Number of Subjects With Any SAEs From 1st Vaccination to Day 181 [Primary Study]
A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. Any is defined as any occurrence of SAE regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3.
Time frame: From Day 1 to Day 181
Number of Subjects With Any SAEs From 1st Vaccination to Day 181 by Each Boostrix Formulation [Primary Study]
A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. Any is defined as any occurrence of SAE regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the safety response to RSVPreF3.
Time frame: From Day 1 to Day 181
Number of Subjects With Any SAEs From 2nd Vaccination to Day 181 Post 2nd Vaccination [Extension Period]
A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. Any is defined as any occurrence of SAE regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies, as the objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3.
Time frame: From the Day of 2nd vaccination to Day 181 post 2nd vaccination
RSV A Neutralizing GMTs at Screening by Each Boostrix Formulation [Primary Study]
Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the immunogenicity response to RSVPreF3.
Time frame: At Screening (Day -7 to Day 1)
RSV A Neutralizing GMTs at Day 8 by Each Boostrix Formulation [Primary Study]
Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the immunogenicity response to RSVPreF3.
Time frame: At Day 8
RSV A Neutralizing GMTs at Day 31 by Each Boostrix Formulation [Primary Study]
Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the immunogenicity response to RSVPreF3.
Time frame: At Day 31
RSV A Neutralizing GMTs at Single Time Point Between 12 to 18 Months Post 1st Vaccination by Each Boostrix Formulation [Primary Study]
Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the immunogenicity response to RSVPreF3.
Time frame: At a single timepoint between 12 to 18 months post 1st vaccination
RSV A Neutralizing GMTs at Single Time Point Between 12 to 18 Months Post 1st Vaccination [Primary Study]
Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60. Analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3.
Time frame: At a single timepoint between 12 to 18 months post 1st vaccination
RSV A Neutralizing GMTs at Day 31 Post 2nd Vaccination [Extension Study]
Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies, as the objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3.
Time frame: At Day 31 post 2nd vaccination
RSV PreF3 IgG GMCs at Screening by Each Boostrix Formulation [Primary Study]
Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody concentration is expressed in EU/mL. The cut-off value for the assay is 25 EU/mL. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the immunogenicity response to RSVPreF3.
Time frame: At Screening (Day -7 to Day 1)
RSV PreF3 IgG GMCs at Day 8 by Each Boostrix Formulation [Primary Study]
Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody concentration is expressed in EU/mL. The cut-off value for the assay is 25 EU/mL. The analysis of this outcome measure was reported for each formulation of the Boostrix (300 μg or 500 μg of aluminum). The objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of Boostrix formulation on the immunogenicity response to RSVPreF3.
Time frame: At Day 8
RSV PreF3 IgG GMCs at Day 31 by Each Boostrix Formulation [Primary Study]
Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody concentration is expressed in EU/mL. The cut-off value for the assay is 25 EU/mL. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the immunogenicity response to RSVPreF3.
Time frame: At Day 31
RSV PreF3 IgG GMCs at Single Time Point Between 12 to 18 Months Post 1st Vaccination by Each Boostrix Formulation [Primary Study]
Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody concentration is expressed in EU/mL. The cut-off value for the assay is 25 EU/mL. The analysis of this outcome measure was reported for each formulation of the Boostrix (300 μg or 500 μg of aluminum). The objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of Boostrix formulation on the immunogenicity response to RSVPreF3.
Time frame: At a single timepoint between 12 to 18 months post 1st vaccination
RSV PreF3 IgG GMCs at Single Time Point Between 12 to 18 Months Post 1st Vaccination [Primary Study]
Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody concentration is expressed in EU/mL. The cut-off value for the assay is 25 EU/mL. Analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3.
Time frame: At a single timepoint between 12 to 18 months post 1st vaccination
RSV PreF3 IgG GMCs at Day 31 Post 2nd Vaccination [Extension Study]
Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies, as the objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3.
Time frame: At Day 31 post 2nd vaccination
Pertussis Toxoid (Anti-PT), Filamentous Hemagglutinin (Anti-FHA) and Pertactin (Anti-PRN) GMCs at Screening by Each Boostrix Formulation [Primary Study]
Serological assays for the determination of IgG antibodies against Bordetella pertussis: anti-PT, anti-FHA and anti-PRN were performed by ELISA. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum).
Time frame: At Screening (Day -7 to Day 1)
Pertussis Toxoid (Anti-PT), Filamentous Hemagglutinin (Anti-FHA) and Pertactin (Anti-PRN) GMCs at Day 31 by Each Boostrix Formulation [Primary Study]
Serological assays for the determination of IgG antibodies against Bordetella pertussis: anti-PT, anti-FHA and anti-PRN were performed by ELISA. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum).
Time frame: At Day 31
Diphtheria (Anti-D) GMC at Screening by Each Boostrix Formulation [Primary Study]
Serological assays for the determination of IgG antibodies against anti-D were performed by ELISA. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum).
Time frame: At Screening (Day -7 to Day 1)
Diphtheria (Anti-D) GMCs at Day 31 by Each Boostrix Formulation [Primary Study]
Serological assays for the determination of IgG antibodies against anti-D were performed by ELISA. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum).
Time frame: At Day 31
Tetanus (Anti-T) GMCs at Screening by Each Boostrix Formulation [Primary Study]
Serological assays for the determination of IgG antibodies against anti-T were performed by ELISA. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum).
Time frame: At Screening (Day -7 to Day 1)
Tetanus (Anti-T) GMCs at Day 31 by Each Boostrix Formulation [Primary Study]
Serological assays for the determination of IgG antibodies against anti-T were performed by ELISA. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum).
Time frame: At Day 31
Pertussis Toxoid (Anti-PT), Filamentous Hemagglutinin (Anti-FHA) and Pertactin (Anti-PRN) GMCs at Screening [Primary Study]
Serological assays for the determination of IgG antibodies against Bordetella pertussis: anti-PT, anti-FHA and anti-PRN were performed by ELISA. Analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies.
Time frame: At Screening (Day -7 to Day 1)
Pertussis Toxoid (Anti-PT), Filamentous Hemagglutinin (Anti-FHA) and Pertactin (Anti-PRN) GMCs at Day 31 [Primary Study]
Serological assays for the determination of IgG antibodies against Bordetella pertussis: anti-PT, anti-FHA and anti-PRN were performed by ELISA. Analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies.
Time frame: At Day 31
Diphtheria (Anti-D) GMCs at Screening [Primary Study]
Serological assays for the determination of IgG antibodies against anti-D were performed by ELISA. Analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies.
Time frame: At Screening (Day -7 to Day 1)
Diphtheria (Anti-D) GMCs at Day 31 [Primary Study]
Serological assays for the determination of IgG antibodies against anti-D were performed by ELISA. Analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies.
Time frame: At Day 31
Tetanus (Anti-T) GMCs at Screening [Primary Study]
Serological assays for the determination of IgG antibodies against anti-T were performed by ELISA. Analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies.
Time frame: At Screening (Day -7 to Day 1)
Tetanus (Anti-T) GMCs at Day 31 [Primary Study]
Serological assays for the determination of IgG antibodies against anti-T were performed by ELISA. Analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies.
Time frame: At Day 31
| Milestone | RSV120_dTpa_RSV120(Pooled) | RSV120_Placebo_RSV120(Pooled) | RSV60_dTpa_RSV120(Pooled) | RSV60_Placebo_RSV120(Pooled) | dTpa_Placebo_RSV120(Pooled) |
|---|---|---|---|---|---|
| Started | 101 | 101 | 103 | 102 | 102 |
| Completed | 95 | 93 | 100 | 100 | 98 |
| Not completed | 6 | 8 | 3 | 2 | 4 |
| Withdrew: Lost to follow-up | 3 | 4 | 1 | 1 | 4 |
| Withdrew: Eligibility criteria not fulfilled (inclusion and exclusion criteria) | 3 | 4 | 2 | 1 | 0 |
| Milestone | RSV120_dTpa_RSV120(Pooled) | RSV120_Placebo_RSV120(Pooled) | RSV60_dTpa_RSV120(Pooled) | RSV60_Placebo_RSV120(Pooled) | dTpa_Placebo_RSV120(Pooled) |
|---|---|---|---|---|---|
| Started | 39 | 41 | 46 | 41 | 46 |
| Completed | 38 | 39 | 45 | 41 | 45 |
| Not completed | 1 | 2 | 1 | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 2 | 1 | 0 | 1 |
Assessed solicited local AEs are: erythema, pain and swelling. Any = occurrence of the adverse event regardless of intensity grade. Any erythema and swelling = adverse event reported with a surface diameter greater than 0 millimeters. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3.
| Percentage of participants | RSV120_dTpa_RSV120(Pooled) | RSV120_Placebo_RSV120(Pooled) | RSV60_dTpa_RSV120(Pooled) | RSV60_Placebo_RSV120(Pooled) | dTpa_Placebo_RSV120(Pooled) |
|---|---|---|---|---|---|
| RSVPreF3 (Left Arm), Erythema | 5.9 (2.2 to 12.5) | 5 (1.6 to 11.3) | 5.8 (2.2 to 12.2) | 5.9 (2.2 to 12.4) | 0 (0 to 3.7) |
| RSVPreF3 (Left Arm), Pain | 51.5 (41.3 to 61.6) | 54 (43.7 to 64) | 52.4 (42.4 to 62.4) | 58.8 (48.6 to 68.5) | 19.2 (12 to 28.3) |
| RSVPreF3 (Left Arm), Swelling | 2 (0.2 to 7) | 7 (2.9 to 13.9) | 2.9 (0.6 to 8.3) | 4.9 (1.6 to 11.1) | 0 (0 to 3.7) |
| dTpa (Right Arm), Erythema | 4 (1.1 to 9.8) | 1 (0 to 5.4) | 4.9 (1.6 to 11) | 1 (0 to 5.3) | 6.1 (2.3 to 12.7) |
| dTpa (Right Arm), Pain | 81.2 (72.2 to 88.3) | 25 (16.9 to 34.7) | 76.7 (67.3 to 84.5) | 18.6 (11.6 to 27.6) | 78.8 (69.4 to 86.4) |
| dTpa (Right Arm), Swelling | 5 (1.6 to 11.2) | 0 (0 to 3.6) | 1.9 (0.2 to 6.8) | 1 (0 to 5.3) | 4 (1.1 to 10) |
Assessed solicited general AEs are: fatigue, gastrointestinal symptoms, headache and fever (body temperature ≥ 38 degree celcius/100.4 degree Farenhit). Any = occurrence of the adverse event regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3.
| Percentage of participants | RSV120_dTpa_RSV120(Pooled) | RSV120_Placebo_RSV120(Pooled) | RSV60_dTpa_RSV120(Pooled) | RSV60_Placebo_RSV120(Pooled) | dTpa_Placebo_RSV120(Pooled) |
|---|---|---|---|---|---|
| Fatigue | 40.6 (30.9 to 50.8) | 39.6 (30 to 49.8) | 37.9 (28.5 to 48) | 32.4 (23.4 to 42.3) | 38.4 (28.8 to 48.7) |
| Gastrointestinal symptoms | 23.8 (15.9 to 33.3) | 28.7 (20.1 to 38.6) | 27.2 (18.9 to 36.8) | 28.4 (19.9 to 38.2) | 28.3 (19.7 to 38.2) |
| Headache | 44.6 (34.7 to 54.8) | 45.5 (35.6 to 55.8) | 35 (25.8 to 45) | 39.2 (29.7 to 49.4) | 37.4 (27.9 to 47.7) |
| Temperature | 2 (0.2 to 7) | 4 (1.1 to 9.8) | 2.9 (0.6 to 8.3) | 3.9 (1.1 to 9.7) | 7.1 (2.9 to 14) |
An unsolicited AE is any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is to be reported as an unsolicited AE. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3.
| Percentage of participants | RSV120_dTpa_RSV120(Pooled) | RSV120_Placebo_RSV120(Pooled) | RSV60_dTpa_RSV120(Pooled) | RSV60_Placebo_RSV120(Pooled) | dTpa_Placebo_RSV120(Pooled) |
|---|---|---|---|---|---|
| Percentage of Subjects With Any Unsolicited AEs [Primary Study] | 38.6 (29.1 to 48.8) | 34.7 (25.5 to 44.8) | 33 (24.1 to 43) | 37.3 (27.9 to 47.4) | 32.4 (23.4 to 42.3) |
A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. Any is defined as any occurrence of SAE regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3.
| Participants | RSV120_dTpa_RSV120(Pooled) | RSV120_Placebo_RSV120(Pooled) | RSV60_dTpa_RSV120(Pooled) | RSV60_Placebo_RSV120(Pooled) | dTpa_Placebo_RSV120(Pooled) |
|---|---|---|---|---|---|
| Number of Subjects With Any SAEs [Primary Study] | 0 | 0 | 0 | 0 | 0 |
Assessed solicited local AEs are: erythema, pain and swelling. Any = occurrence of the adverse event regardless of intensity grade. Any erythema and swelling = adverse event reported with a surface diameter greater than 0 millimeters. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies.The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3.
| Percentage of participants | RSV120_dTpa_RSV120(Pooled) | RSV120_Placebo_RSV120(Pooled) | RSV60_dTpa_RSV120(Pooled) | RSV60_Placebo_RSV120(Pooled) | dTpa_Placebo_RSV120(Pooled) |
|---|---|---|---|---|---|
| Erythema | 17.9 (7.5 to 33.5) | 10.3 (2.9 to 24.2) | 8.7 (2.4 to 20.8) | 14.6 (5.6 to 29.2) | 2.3 (0.1 to 12) |
| Pain | 87.2 (72.6 to 95.7) | 87.2 (72.6 to 95.7) | 80.4 (66.1 to 90.6) | 85.4 (70.8 to 94.4) | 38.6 (24.4 to 54.5) |
| Swelling | 12.8 (4.3 to 27.4) | 7.7 (1.6 to 20.9) | 8.7 (2.4 to 20.8) | 4.9 (0.6 to 16.5) | 2.3 (0.1 to 12) |
Assessed solicited general AEs are: fatigue, gastrointestinal symptoms, headache and fever(body temperature ≥ 38 degree celcius/100.4 degree Farenhit). Any = occurrence of the adverse event regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3.
| Percentage of participants | RSV120_dTpa_RSV120(Pooled) | RSV120_Placebo_RSV120(Pooled) | RSV60_dTpa_RSV120(Pooled) | RSV60_Placebo_RSV120(Pooled) | dTpa_Placebo_RSV120(Pooled) |
|---|---|---|---|---|---|
| Fatigue | 25.6 (13 to 42.1) | 33.3 (19.1 to 50.2) | 37 (23.2 to 52.5) | 46.3 (30.7 to 62.6) | 34.1 (20.5 to 49.9) |
| Gastrointestinal symptoms | 10.3 (2.9 to 24.2) | 20.5 (9.3 to 36.5) | 15.2 (6.3 to 28.9) | 24.4 (12.4 to 40.3) | 13.6 (5.2 to 27.4) |
| Headache | 28.2 (15 to 44.9) | 33.3 (19.1 to 50.2) | 32.6 (19.5 to 48) | 56.1 (39.7 to 71.5) | 31.8 (18.6 to 47.6) |
| Temperature | 0 (0 to 9) | 0 (0 to 9) | 2.2 (0.1 to 11.5) | 9.8 (2.7 to 23.1) | 2.3 (0.1 to 12) |
An unsolicited AE is any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is to be reported as an unsolicited AE. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3.
| Percentage of participants | RSV120_dTpa_RSV120(Pooled) | RSV120_Placebo_RSV120(Pooled) | RSV60_dTpa_RSV120(Pooled) | RSV60_Placebo_RSV120(Pooled) | dTpa_Placebo_RSV120(Pooled) |
|---|---|---|---|---|---|
| Percentage of Subjects With Any Unsolicited AEs [Extension Period] | 18 (8 to 34) | 20 (9 to 35) | 20 (9 to 34) | 29 (16 to 46) | 20 (9 to 34) |
A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. Any is defined as any occurrence of SAE regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3.
| Participants | RSV120_dTpa_RSV120(Pooled) | RSV120_Placebo_RSV120(Pooled) | RSV60_dTpa_RSV120(Pooled) | RSV60_Placebo_RSV120(Pooled) | dTpa_Placebo_RSV120(Pooled) |
|---|---|---|---|---|---|
| Number of Subjects With Any SAEs [Extension Period] | 0 | 0 | 0 | 1 | 0 |
Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60 (Estimated Dilution 60). The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3.
| Titers (ED60) | RSV120_dTpa_RSV120(Pooled) | RSV120_Placebo_RSV120(Pooled) | RSV60_dTpa_RSV120(Pooled) | RSV60_Placebo_RSV120(Pooled) | dTpa_Placebo_RSV120(Pooled) |
|---|---|---|---|---|---|
| RSV A Neutralizing Antibody Geometric Mean Titers (GMTs) at Screening [Primary Study] | 875 (745 to 1027) | 1022 (856 to 1222) | 1135 (959 to 1342) | 771 (673 to 883) | 1050 (896 to 1231) |
Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3.
| Titers (ED60) | RSV120_dTpa_RSV120(Pooled) | RSV120_Placebo_RSV120(Pooled) | RSV60_dTpa_RSV120(Pooled) | RSV60_Placebo_RSV120(Pooled) | dTpa_Placebo_RSV120(Pooled) |
|---|---|---|---|---|---|
| RSV A Neutralizing Antibody GMTs at Day 8 [Primary Study] | 14166 (12213 to 16431) | 14285 (11999 to 17008) | 10185 (8514 to 12183) | 10590 (8994 to 12469) | 783 (661 to 929) |
Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3.
| Titers (ED60) | RSV120_dTpa_RSV120(Pooled) | RSV120_Placebo_RSV120(Pooled) | RSV60_dTpa_RSV120(Pooled) | RSV60_Placebo_RSV120(Pooled) | dTpa_Placebo_RSV120(Pooled) |
|---|---|---|---|---|---|
| RSV A Neutralizing Antibody GMTs at Day 31 [Primary Study] | 9836 (8252 to 11725) | 11038 (9160 to 13301) | 9214 (7806 to 10876) | 8739 (7561 to 10101) | 845 (705 to 1013) |
Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by Enzyme-linked immunosorbent assay (ELISA ). The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3.
| ELISA Units per milliliter (EU/mL) | RSV120_dTpa_RSV120(Pooled) | RSV120_Placebo_RSV120(Pooled) | RSV60_dTpa_RSV120(Pooled) | RSV60_Placebo_RSV120(Pooled) | dTpa_Placebo_RSV120(Pooled) |
|---|---|---|---|---|---|
| RSV PreF3 IgG Antibody Geometric Mean Concentration (GMCs) at Screening [Primary Study] | 6611 (5857 to 7461) | 6751 (5982 to 7620) | 7449 (6534 to 8492) | 6172 (5570 to 6840) | 6454 (5771 to 7217) |
Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by Enzyme-linked immunosorbent assay (ELISA). The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3.
| EU/mL | RSV120_dTpa_RSV120(Pooled) | RSV120_Placebo_RSV120(Pooled) | RSV60_dTpa_RSV120(Pooled) | RSV60_Placebo_RSV120(Pooled) | dTpa_Placebo_RSV120(Pooled) |
|---|---|---|---|---|---|
| RSV PreF3 IgG GMCs at Day 8 [Primary Study] | 156568 (137244 to 178613) | 146708 (128639 to 167315) | 101662 (89783 to 115113) | 118670 (106004 to 132850) | 5780 (5145 to 6494) |
Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by Enzyme-linked immunosorbent assay (ELISA). Analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3.
| EU/mL | RSV120_dTpa_RSV120(Pooled) | RSV120_Placebo_RSV120(Pooled) | RSV60_dTpa_RSV120(Pooled) | RSV60_Placebo_RSV120(Pooled) | dTpa_Placebo_RSV120(Pooled) |
|---|---|---|---|---|---|
| RSV PreF3 IgG GMCs at Day 31 [Primary Study] | 101813 (89290 to 116092) | 106082 (93597 to 120231) | 86273 (77415 to 96145) | 88938 (79738 to 99200) | 6149 (5474 to 6908) |
Assessed solicited local AEs are: erythema, pain and swelling. Any = occurrence of the adverse event regardless of intensity grade. Any erythema and swelling = adverse event reported with a surface diameter greater than 0 millimeters. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the safety response to RSVPreF3.
| Percentage of participants | RSV120_dTpa_RSV120(EX-US) | RSV120_Placebo_RSV120(EX-US) | RSV60_dTpa_RSV120(EX-US) | RSV60_Placebo_RSV120(EX-US) | dTpa_Placebo_RSV120(EX-US) | RSV120_dTpa_RSV120(US) | RSV120_Placebo_RSV120(US) | RSV60_dTpa_RSV120(US) | RSV60_Placebo_RSV120(US) | dTpa_Placebo_RSV120(US) |
|---|---|---|---|---|---|---|---|---|---|---|
| Left Arm, Erythema | 6 (1.3 to 16.5) | 4.1 (0.5 to 14) | 5.9 (1.2 to 16.2) | 2 (0 to 10.4) | 0 (0 to 7.3) | 5.9 (1.2 to 16.2) | 5.9 (1.2 to 16.2) | 5.8 (1.2 to 15.9) | 9.8 (3.3 to 21.4) | 0 (0 to 7.1) |
| Left Arm, Pain | 46 (31.8 to 60.7) | 53.1 (38.3 to 67.5) | 52.9 (38.5 to 67.1) | 60.8 (46.1 to 74.2) | 16.3 (7.3 to 29.7) | 56.9 (42.2 to 70.7) | 54.9 (40.3 to 68.9) | 51.9 (37.6 to 66) | 56.9 (42.2 to 70.7) | 22 (11.5 to 36) |
| Left Arm, Swelling | 2 (0.1 to 10.6) | 6.1 (1.3 to 16.9) | 3.9 (0.5 to 13.5) | 2 (0 to 10.4) | 0 (0 to 7.3) | 2 (0 to 10.4) | 7.8 (2.2 to 18.9) | 1.9 (0 to 10.3) | 7.8 (2.2 to 18.9) | 0 (0 to 7.1) |
| Right Arm, Erythema | 4 (0.5 to 13.7) | 2 (0.1 to 10.9) | 2 (0 to 10.4) | 2 (0 to 10.4) | 6.1 (1.3 to 16.9) | 3.9 (0.5 to 13.5) | 0 (0 to 7) | 7.7 (2.1 to 18.5) | 0 (0 to 7) | 6 (1.3 to 16.5) |
| Right Arm, Pain | 86 (73.3 to 94.2) | 18.4 (8.8 to 32) | 88.2 (76.1 to 95.6) | 23.5 (12.8 to 37.5) | 79.6 (65.7 to 89.8) | 76.5 (62.5 to 87.2) | 31.4 (19.1 to 45.9) | 65.4 (50.9 to 78) | 13.7 (5.7 to 26.3) | 78 (64 to 88.5) |
| Right Arm, Swelling | 6 (1.3 to 16.5) | 0 (0 to 7.3) | 3.9 (0.5 to 13.5) | 2 (0 to 10.4) | 6.1 (1.3 to 16.9) | 3.9 (0.5 to 13.5) | 0 (0 to 7) | 0 (0 to 6.8) | 0 (0 to 7) | 2 (0.1 to 10.6) |
Assessed solicited general AEs are: fatigue, gastrointestinal symptoms, headache and fever(body temperature ≥ 38 degree celcius/100.4 degree Farenhit). Any = occurrence of the adverse event regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the safety response to RSVPreF3.
| Percentage of participants | RSV120_dTpa_RSV120(EX-US) | RSV120_Placebo_RSV120(EX-US) | RSV60_dTpa_RSV120(EX-US) | RSV60_Placebo_RSV120(EX-US) | dTpa_Placebo_RSV120(EX-US) | RSV120_dTpa_RSV120(US) | RSV120_Placebo_RSV120(US) | RSV60_dTpa_RSV120(US) | RSV60_Placebo_RSV120(US) | dTpa_Placebo_RSV120(US) |
|---|---|---|---|---|---|---|---|---|---|---|
| Fatigue | 36 (22.9 to 50.8) | 36.7 (23.4 to 51.7) | 39.2 (25.8 to 53.9) | 29.4 (17.5 to 43.8) | 34.7 (21.7 to 49.6) | 45.1 (31.1 to 59.7) | 42.3 (28.7 to 56.8) | 36.5 (23.6 to 51) | 35.3 (22.4 to 49.9) | 42 (28.2 to 56.8) |
| Gastrointestinal symptoms | 22 (11.5 to 36) | 28.6 (16.6 to 43.3) | 23.5 (12.8 to 37.5) | 29.4 (17.5 to 43.8) | 30.6 (18.3 to 45.4) | 25.5 (14.3 to 39.6) | 28.8 (17.1 to 43.1) | 30.8 (18.7 to 45.1) | 27.5 (15.9 to 41.7) | 26 (14.6 to 40.3) |
| Headache | 46 (31.8 to 60.7) | 38.8 (25.2 to 53.8) | 31.4 (19.1 to 45.9) | 45.1 (31.1 to 59.7) | 40.8 (27 to 55.8) | 43.1 (29.3 to 57.8) | 51.9 (37.6 to 66) | 38.5 (25.3 to 53) | 33.3 (20.8 to 47.9) | 34 (21.2 to 48.8) |
| Temperature | 4 (0.5 to 13.7) | 6.1 (1.3 to 16.9) | 3.9 (0.5 to 13.5) | 5.9 (1.2 to 16.2) | 12.2 (4.6 to 24.8) | 0 (0 to 7) | 1.9 (0 to 10.3) | 1.9 (0 to 10.3) | 2 (0 to 10.4) | 2 (0.1 to 10.6) |
An unsolicited AE is any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is to be reported as an unsolicited AE. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the safety response to RSVPreF3.
| Percentage of participants | RSV120_dTpa_RSV120(EX-US) | RSV120_Placebo_RSV120(EX-US) | RSV60_dTpa_RSV120(EX-US) | RSV60_Placebo_RSV120(EX-US) | dTpa_Placebo_RSV120(EX-US) | RSV120_dTpa_RSV120(US) | RSV120_Placebo_RSV120(US) | RSV60_dTpa_RSV120(US) | RSV60_Placebo_RSV120(US) | dTpa_Placebo_RSV120(US) |
|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Subjects With Any Unsolicited AEs by Each Boostrix Formulation [Primary Study] | 38 (24.7 to 52.8) | 36.7 (23.4 to 51.7) | 39.2 (25.8 to 53.9) | 43.1 (29.3 to 57.8) | 33.3 (20.8 to 47.9) | 39.2 (25.8 to 53.9) | 32.7 (20.3 to 47.1) | 26.9 (15.6 to 41) | 31.4 (19.1 to 45.9) | 31.4 (19.1 to 45.9) |
A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. Any is defined as any occurrence of SAE regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the safety response to RSVPreF3.
| Participants | RSV120_dTpa_RSV120(EX-US) | RSV120_Placebo_RSV120(EX-US) | RSV60_dTpa_RSV120(EX-US) | RSV60_Placebo_RSV120(EX-US) | dTpa_Placebo_RSV120(EX-US) | RSV120_dTpa_RSV120(US) | RSV120_Placebo_RSV120(US) | RSV60_dTpa_RSV120(US) | RSV60_Placebo_RSV120(US) | dTpa_Placebo_RSV120(US) |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Subjects With Any SAEs by Each Boostrix Formulation [Primary Study] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. Any is defined as any occurrence of SAE regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3.
| Participants | RSV120_dTpa_RSV120(Pooled) | RSV120_Placebo_RSV120(Pooled) | RSV60_dTpa_RSV120(Pooled) | RSV60_Placebo_RSV120(Pooled) | dTpa_Placebo_RSV120(Pooled) |
|---|---|---|---|---|---|
| Number of Subjects With Any SAEs From 1st Vaccination to Day 181 [Primary Study] | 1 | 0 | 0 | 0 | 0 |
A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. Any is defined as any occurrence of SAE regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the safety response to RSVPreF3.
| Participants | RSV120_dTpa_RSV120(EX-US) | RSV120_Placebo_RSV120(EX-US) | RSV60_dTpa_RSV120(EX-US) | RSV60_Placebo_RSV120(EX-US) | dTpa_Placebo_RSV120(EX-US) | RSV120_dTpa_RSV120(US) | RSV120_Placebo_RSV120(US) | RSV60_dTpa_RSV120(US) | RSV60_Placebo_RSV120(US) | dTpa_Placebo_RSV120(US) |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Subjects With Any SAEs From 1st Vaccination to Day 181 by Each Boostrix Formulation [Primary Study] | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. Any is defined as any occurrence of SAE regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies, as the objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3.
| Participants | RSV120_dTpa_RSV120(Pooled) | RSV120_Placebo_RSV120(Pooled) | RSV60_dTpa_RSV120(Pooled) | RSV60_Placebo_RSV120(Pooled) | dTpa_Placebo_RSV120(Pooled) |
|---|---|---|---|---|---|
| Number of Subjects With Any SAEs From 2nd Vaccination to Day 181 Post 2nd Vaccination [Extension Period] | 0 | 0 | 0 | 1 | 0 |
Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the immunogenicity response to RSVPreF3.
| Titers (ED60) | RSV120_dTpa_RSV120(EX-US) | RSV120_Placebo_RSV120(EX-US) | RSV60_dTpa_RSV120(EX-US) | RSV60_Placebo_RSV120(EX-US) | dTpa_Placebo_RSV120(EX-US) | RSV120_dTpa_RSV120(US) | RSV120_Placebo_RSV120(US) | RSV60_dTpa_RSV120(US) | RSV60_Placebo_RSV120(US) | dTpa_Placebo_RSV120(US) |
|---|---|---|---|---|---|---|---|---|---|---|
| RSV A Neutralizing GMTs at Screening by Each Boostrix Formulation [Primary Study] | 777 (625 to 966) | 1009 (798 to 1277) | 989 (749 to 1307) | 777 (631 to 956) | 956 (740 to 1236) | 981 (773 to 1245) | 1035 (786 to 1362) | 1298 (1070 to 1574) | 765 (638 to 917) | 1154 (952 to 1399) |
Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the immunogenicity response to RSVPreF3.
| Titers (ED60) | RSV120_dTpa_RSV120(EX-US) | RSV120_Placebo_RSV120(EX-US) | RSV60_dTpa_RSV120(EX-US) | RSV60_Placebo_RSV120(EX-US) | dTpa_Placebo_RSV120(EX-US) | RSV120_dTpa_RSV120(US) | RSV120_Placebo_RSV120(US) | RSV60_dTpa_RSV120(US) | RSV60_Placebo_RSV120(US) | dTpa_Placebo_RSV120(US) |
|---|---|---|---|---|---|---|---|---|---|---|
| RSV A Neutralizing GMTs at Day 8 by Each Boostrix Formulation [Primary Study] | 14523 (11831 to 17827) | 15458 (12424 to 19231) | 10677 (8146 to 13993) | 11128 (8885 to 13939) | 698 (530 to 918) | 13818 (11070 to 17248) | 13264 (10075 to 17462) | 9715 (7612 to 12400) | 10077 (7897 to 12858) | 884 (722 to 1082) |
Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the immunogenicity response to RSVPreF3.
| Titers (ED60) | RSV120_dTpa_RSV120(EX-US) | RSV120_Placebo_RSV120(EX-US) | RSV60_dTpa_RSV120(EX-US) | RSV60_Placebo_RSV120(EX-US) | dTpa_Placebo_RSV120(EX-US) | RSV120_dTpa_RSV120(US) | RSV120_Placebo_RSV120(US) | RSV60_dTpa_RSV120(US) | RSV60_Placebo_RSV120(US) | dTpa_Placebo_RSV120(US) |
|---|---|---|---|---|---|---|---|---|---|---|
| RSV A Neutralizing GMTs at Day 31 by Each Boostrix Formulation [Primary Study] | 9838 (7987 to 12118) | 10800 (8675 to 13446) | 8754 (6821 to 11236) | 8141 (6545 to 10125) | 767 (575 to 1023) | 9834 (7354 to 13152) | 11276 (8283 to 15351) | 9698 (7735 to 12159) | 9395 (7726 to 11425) | 930 (740 to 1168) |
Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the immunogenicity response to RSVPreF3.
| Titers (ED60) | RSV120_dTpa_RSV120(EX-US) | RSV120_Placebo_RSV120(EX-US) | RSV60_dTpa_RSV120(EX-US) | RSV60_Placebo_RSV120(EX-US) | dTpa_Placebo_RSV120(EX-US) | RSV120_dTpa_RSV120(US) | RSV120_Placebo_RSV120(US) | RSV60_dTpa_RSV120(US) | RSV60_Placebo_RSV120(US) | dTpa_Placebo_RSV120(US) |
|---|---|---|---|---|---|---|---|---|---|---|
| RSV A Neutralizing GMTs at Single Time Point Between 12 to 18 Months Post 1st Vaccination by Each Boostrix Formulation [Primary Study] | 2034 (1458 to 2836) | 2869 (1998 to 4119) | 3086 (2143 to 4445) | 2200 (1522 to 3180) | 675 (495 to 920) | 2014 (1190 to 3411) | 2960 (1190 to 7362) | 2474 (1741 to 3517) | 2569 (1586 to 4160) | 969 (602 to 1560) |
Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60. Analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3.
| Titers (ED60) | RSV120_dTpa_RSV120(Pooled) | RSV120_Placebo_RSV120(Pooled) | RSV60_dTpa_RSV120(Pooled) | RSV60_Placebo_RSV120(Pooled) | dTpa_Placebo_RSV120(Pooled) |
|---|---|---|---|---|---|
| RSV A Neutralizing GMTs at Single Time Point Between 12 to 18 Months Post 1st Vaccination [Primary Study] | 2027 (1546 to 2656) | 2889 (2086 to 4001) | 2885 (2204 to 3778) | 2302 (1730 to 3064) | 759 (588 to 980) |
Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies, as the objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3.
| Titers (ED60) | RSV120_dTpa_RSV120(Pooled) | RSV120_Placebo_RSV120(Pooled) | RSV60_dTpa_RSV120(Pooled) | RSV60_Placebo_RSV120(Pooled) | dTpa_Placebo_RSV120(Pooled) |
|---|---|---|---|---|---|
| RSV A Neutralizing GMTs at Day 31 Post 2nd Vaccination [Extension Study] | 3892 (3016 to 5022) | 5071 (3848 to 6683) | 4779 (3747 to 6094) | 4920 (3886 to 6231) | 8200 (6380 to 10539) |
Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody concentration is expressed in EU/mL. The cut-off value for the assay is 25 EU/mL. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the immunogenicity response to RSVPreF3.
| EU/mL | RSV120_dTpa_RSV120(EX-US) | RSV120_Placebo_RSV120(EX-US) | RSV60_dTpa_RSV120(EX-US) | RSV60_Placebo_RSV120(EX-US) | dTpa_Placebo_RSV120(EX-US) | RSV120_dTpa_RSV120(US) | RSV120_Placebo_RSV120(US) | RSV60_dTpa_RSV120(US) | RSV60_Placebo_RSV120(US) | dTpa_Placebo_RSV120(US) |
|---|---|---|---|---|---|---|---|---|---|---|
| RSV PreF3 IgG GMCs at Screening by Each Boostrix Formulation [Primary Study] | 6240 (5159 to 7548) | 6524 (5597 to 7604) | 7237 (5905 to 8869) | 6106 (5275 to 7067) | 5907 (5077 to 6873) | 6987 (5975 to 8170) | 6978 (5764 to 8447) | 7662 (6447 to 9107) | 6240 (5375 to 7245) | 7051 (5973 to 8324) |
Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody concentration is expressed in EU/mL. The cut-off value for the assay is 25 EU/mL. The analysis of this outcome measure was reported for each formulation of the Boostrix (300 μg or 500 μg of aluminum). The objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of Boostrix formulation on the immunogenicity response to RSVPreF3.
| EU/mL | RSV120_dTpa_RSV120(EX-US) | RSV120_Placebo_RSV120(EX-US) | RSV60_dTpa_RSV120(EX-US) | RSV60_Placebo_RSV120(EX-US) | dTpa_Placebo_RSV120(EX-US) | RSV120_dTpa_RSV120(US) | RSV120_Placebo_RSV120(US) | RSV60_dTpa_RSV120(US) | RSV60_Placebo_RSV120(US) | dTpa_Placebo_RSV120(US) |
|---|---|---|---|---|---|---|---|---|---|---|
| RSV PreF3 IgG GMCs at Day 8 by Each Boostrix Formulation [Primary Study] | 155721 (133435 to 181728) | 143104 (126138 to 162352) | 100064 (84699 to 118216) | 123475 (107405 to 141950) | 5523 (4700 to 6490) | 157403 (126554 to 195772) | 150184 (119250 to 189142) | 103286 (85400 to 124919) | 114053 (95089 to 136799) | 6061 (5097 to 7207) |
Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody concentration is expressed in EU/mL. The cut-off value for the assay is 25 EU/mL. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the immunogenicity response to RSVPreF3.
| EU/mL | RSV120_dTpa_RSV120(EX-US) | RSV120_Placebo_RSV120(EX-US) | RSV60_dTpa_RSV120(EX-US) | RSV60_Placebo_RSV120(EX-US) | dTpa_Placebo_RSV120(EX-US) | RSV120_dTpa_RSV120(US) | RSV120_Placebo_RSV120(US) | RSV60_dTpa_RSV120(US) | RSV60_Placebo_RSV120(US) | dTpa_Placebo_RSV120(US) |
|---|---|---|---|---|---|---|---|---|---|---|
| RSV PreF3 IgG GMCs at Day 31 by Each Boostrix Formulation [Primary Study] | 94254 (80742 to 110026) | 95113 (83282 to 108624) | 84509 (72281 to 98805) | 81915 (70291 to 95460) | 5600 (4777 to 6565) | 109978 (88643 to 136446) | 118052 (95525 to 145892) | 88075 (75406 to 102872) | 96727 (82608 to 113258) | 6739 (5678 to 7999) |
Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody concentration is expressed in EU/mL. The cut-off value for the assay is 25 EU/mL. The analysis of this outcome measure was reported for each formulation of the Boostrix (300 μg or 500 μg of aluminum). The objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of Boostrix formulation on the immunogenicity response to RSVPreF3.
| EU/mL | RSV120_dTpa_RSV120(EX-US) | RSV120_Placebo_RSV120(EX-US) | RSV60_dTpa_RSV120(EX-US) | RSV60_Placebo_RSV120(EX-US) | dTpa_Placebo_RSV120(EX-US) | RSV120_dTpa_RSV120(US) | RSV120_Placebo_RSV120(US) | RSV60_dTpa_RSV120(US) | RSV60_Placebo_RSV120(US) | dTpa_Placebo_RSV120(US) |
|---|---|---|---|---|---|---|---|---|---|---|
| RSV PreF3 IgG GMCs at Single Time Point Between 12 to 18 Months Post 1st Vaccination by Each Boostrix Formulation [Primary Study] | 18832 (15141 to 23423) | 20894 (16466 to 26512) | 23189 (18629 to 28864) | 20720 (16689 to 25726) | 5014 (3932 to 6392) | 18127 (10969 to 29958) | 19641 (9143 to 42195) | 22905 (17801 to 29471) | 22233 (15931 to 31029) | 6811 (5005 to 9269) |
Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody concentration is expressed in EU/mL. The cut-off value for the assay is 25 EU/mL. Analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3.
| EU/mL | RSV120_dTpa_RSV120(Pooled) | RSV120_Placebo_RSV120(Pooled) | RSV60_dTpa_RSV120(Pooled) | RSV60_Placebo_RSV120(Pooled) | dTpa_Placebo_RSV120(Pooled) |
|---|---|---|---|---|---|
| RSV PreF3 IgG GMCs at Single Time Point Between 12 to 18 Months Post 1st Vaccination [Primary Study] | 18570 (14961 to 23049) | 20605 (16333 to 25995) | 23102 (19586 to 27249) | 21152 (17777 to 25168) | 5540 (4581 to 6700) |
Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies, as the objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3.
| (IU/mL) | RSV120_dTpa_RSV120(Pooled) | RSV120_Placebo_RSV120(Pooled) | RSV60_dTpa_RSV120(Pooled) | RSV60_Placebo_RSV120(Pooled) | dTpa_Placebo_RSV120(Pooled) |
|---|---|---|---|---|---|
| RSV PreF3 IgG GMCs at Day 31 Post 2nd Vaccination [Extension Study] | 41399 (34806 to 49241) | 42943 (37226 to 49537) | 43977 (38784 to 49865) | 45680 (38574 to 54094) | 86934 (75442 to 100177) |
Serological assays for the determination of IgG antibodies against Bordetella pertussis: anti-PT, anti-FHA and anti-PRN were performed by ELISA. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum).
| International Units Per mL (IU/mL) | RSV120_dTpa_RSV120(EX-US) | RSV60_dTpa_RSV120(EX-US) | dTpa_Placebo_RSV120(EX-US) | RSV120_dTpa_RSV120(US) | RSV60_dTpa_RSV120(US) | dTpa_Placebo_RSV120(US) |
|---|---|---|---|---|---|---|
| anti-PT | 7.39 (5.11 to 10.68) | 7.64 (5.47 to 10.66) | 6.65 (4.66 to 9.47) | 7.55 (5.34 to 10.66) | 5.66 (4.06 to 7.88) | 7.17 (4.94 to 10.41) |
| anti-FHA | 32.8 (23 to 46.7) | 34.5 (24.3 to 49.1) | 29.3 (22 to 38.9) | 31 (22.7 to 42.4) | 29.6 (22.5 to 38.9) | 28 (21 to 37.4) |
| anti-PRN | 43.2 (27.9 to 66.7) | 39 (25.3 to 60.1) | 28.1 (18.2 to 43.4) | 42.1 (27.6 to 64.2) | 40.1 (26.9 to 60) | 28.7 (17.9 to 46.1) |
Serological assays for the determination of IgG antibodies against Bordetella pertussis: anti-PT, anti-FHA and anti-PRN were performed by ELISA. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum).
| (IU/mL) | RSV120_dTpa_RSV120(EX-US) | RSV60_dTpa_RSV120(EX-US) | dTpa_Placebo_RSV120(EX-US) | RSV120_dTpa_RSV120(US) | RSV60_dTpa_RSV120(US) | dTpa_Placebo_RSV120(US) |
|---|---|---|---|---|---|---|
| anti-PT | 57.36 (41.82 to 78.69) | 54.95 (44.78 to 67.44) | 79.16 (62.67 to 99.98) | 43.76 (34.1 to 56.17) | 36.98 (28.25 to 48.42) | 44.99 (34.81 to 58.15) |
| anti-FHA | 237.1 (194.1 to 289.5) | 210.6 (168.5 to 263.1) | 303.6 (241.6 to 381.5) | 186.5 (149.8 to 232.3) | 176.7 (139.3 to 224.1) | 232.9 (182.2 to 297.8) |
| anti-PRN | 309.5 (226.7 to 422.6) | 214.7 (166.8 to 276.4) | 395.1 (290.3 to 537.6) | 217.7 (153.7 to 308.3) | 228.1 (161.9 to 321.5) | 331.4 (238.4 to 460.5) |
Serological assays for the determination of IgG antibodies against anti-D were performed by ELISA. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum).
| (IU/mL) | RSV120_dTpa_RSV120(EX-US) | RSV60_dTpa_RSV120(EX-US) | dTpa_Placebo_RSV120(EX-US) | RSV120_dTpa_RSV120(US) | RSV60_dTpa_RSV120(US) | dTpa_Placebo_RSV120(US) |
|---|---|---|---|---|---|---|
| Diphtheria (Anti-D) GMC at Screening by Each Boostrix Formulation [Primary Study] | 0.26 (0.18 to 0.39) | 0.27 (0.17 to 0.42) | 0.23 (0.16 to 0.32) | 0.46 (0.33 to 0.64) | 0.55 (0.42 to 0.73) | 0.58 (0.43 to 0.78) |
Serological assays for the determination of IgG antibodies against anti-D were performed by ELISA. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum).
| (IU/mL) | RSV120_dTpa_RSV120(EX-US) | RSV60_dTpa_RSV120(EX-US) | dTpa_Placebo_RSV120(EX-US) | RSV120_dTpa_RSV120(US) | RSV60_dTpa_RSV120(US) | dTpa_Placebo_RSV120(US) |
|---|---|---|---|---|---|---|
| Diphtheria (Anti-D) GMCs at Day 31 by Each Boostrix Formulation [Primary Study] | 1.3 (0.97 to 1.73) | 1.18 (0.85 to 1.63) | 1.76 (1.25 to 2.48) | 2.11 (1.61 to 2.76) | 2.2 (1.72 to 2.81) | 3.29 (2.62 to 4.14) |
Serological assays for the determination of IgG antibodies against anti-T were performed by ELISA. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum).
| (IU/mL) | RSV120_dTpa_RSV120(EX-US) | RSV60_dTpa_RSV120(EX-US) | dTpa_Placebo_RSV120(EX-US) | RSV120_dTpa_RSV120(US) | RSV60_dTpa_RSV120(US) | dTpa_Placebo_RSV120(US) |
|---|---|---|---|---|---|---|
| Tetanus (Anti-T) GMCs at Screening by Each Boostrix Formulation [Primary Study] | 1.14 (0.87 to 1.5) | 1.1 (0.78 to 1.54) | 0.88 (0.64 to 1.22) | 1.35 (1.01 to 1.81) | 1.56 (1.27 to 1.92) | 1.68 (1.29 to 2.19) |
Serological assays for the determination of IgG antibodies against anti-T were performed by ELISA. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum).
| (IU/mL) | RSV120_dTpa_RSV120(EX-US) | RSV60_dTpa_RSV120(EX-US) | dTpa_Placebo_RSV120(EX-US) | RSV120_dTpa_RSV120(US) | RSV60_dTpa_RSV120(US) | dTpa_Placebo_RSV120(US) |
|---|---|---|---|---|---|---|
| Tetanus (Anti-T) GMCs at Day 31 by Each Boostrix Formulation [Primary Study] | 5.57 (4.64 to 6.7) | 5.3 (4.52 to 6.21) | 6.74 (5.79 to 7.84) | 6.09 (4.98 to 7.45) | 6.27 (5.29 to 7.44) | 8.32 (6.88 to 10.05) |
Serological assays for the determination of IgG antibodies against Bordetella pertussis: anti-PT, anti-FHA and anti-PRN were performed by ELISA. Analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies.
| IU/mL | RSV120_dTpa_RSV120(Pooled) | RSV60_dTpa_RSV120(Pooled) | dTpa_Placebo_RSV120(Pooled) |
|---|---|---|---|
| Anti-PT | 7.47 (5.83 to 9.57) | 6.56 (5.20 to 8.28) | 6.90 (5.36 to 8.89) |
| Anti-FHA | 31.9 (25.3 to 40.2) | 31.9 (25.6 to 39.8) | 28.6 (23.5 to 34.9) |
| Anti-PRN | 42.6 (31.6 to 57.4) | 39.6 (29.6 to 52.9) | 28.4 (20.7 to 38.9) |
Serological assays for the determination of IgG antibodies against Bordetella pertussis: anti-PT, anti-FHA and anti-PRN were performed by ELISA. Analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies.
| IU/mL | RSV120_dTpa_RSV120(Pooled) | RSV60_dTpa_RSV120(Pooled) | dTpa_Placebo_RSV120(Pooled) |
|---|---|---|---|
| Anti-PT | 50.10 (41.04 to 61.17) | 45.08 (38.00 to 53.48) | 59.51 (49.71 to 71.23) |
| Anti-FHA | 210.3 (181.4 to 243.8) | 192.9 (164.2 to 226.6) | 265.6 (224.7 to 313.8) |
| Anti-PRN | 259.6 (205.8 to 327.4) | 221.3 (179.5 to 272.9) | 361.1 (289.1 to 451.1) |
Serological assays for the determination of IgG antibodies against anti-D were performed by ELISA. Analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies.
| IU/mL | RSV120_dTpa_RSV120(Pooled) | RSV60_dTpa_RSV120(Pooled) | dTpa_Placebo_RSV120(Pooled) |
|---|---|---|---|
| Diphtheria (Anti-D) GMCs at Screening [Primary Study] | 0.35 (0.27 to 0.45) | 0.39 (0.30 to 0.51) | 0.36 (0.28 to 0.47) |
Serological assays for the determination of IgG antibodies against anti-D were performed by ELISA. Analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies.
| IU/mL | RSV120_dTpa_RSV120(Pooled) | RSV60_dTpa_RSV120(Pooled) | dTpa_Placebo_RSV120(Pooled) |
|---|---|---|---|
| Diphtheria (Anti-D) GMCs at Day 31 [Primary Study] | 1.65 (1.35 to 2.01) | 1.59 (1.29 to 1.97) | 2.42 (1.96 to 2.99) |
Serological assays for the determination of IgG antibodies against anti-T were performed by ELISA. Analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies.
| IU/mL | RSV120_dTpa_RSV120(Pooled) | RSV60_dTpa_RSV120(Pooled) | dTpa_Placebo_RSV120(Pooled) |
|---|---|---|---|
| Tetanus (Anti-T) GMCs at Screening [Primary Study] | 1.24 (1.02 to 1.51) | 1.31 (1.08 to 1.60) | 1.22 (0.98 to 1.51) |
Serological assays for the determination of IgG antibodies against anti-T were performed by ELISA. Analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies.
| IU/mL | RSV120_dTpa_RSV120(Pooled) | RSV60_dTpa_RSV120(Pooled) | dTpa_Placebo_RSV120(Pooled) |
|---|---|---|---|
| Tetanus (Anti-T) GMCs at Day 31 [Primary Study] | 5.83 (5.10 to 6.66) | 5.76 (5.13 to 6.47) | 7.49 (6.64 to 8.46) |
Collected over Solicited adverse events were collected during the 7-day follow-up period and unsolicited adverse events during the 30-day follow-up period after any vaccination. Serious adverse events were collected from Day 1 (Primary Study) to the Study End (Day 181 after the second RSVPreF3 vaccination, Extension Study).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RSV120_dTpa_RSV120(Pooled) | 0/101 (0%) | 1/101 (1%) | 92/101 (91.1%) |
| RSV120_Placebo_RSV120(Pooled) | 0/101 (0%) | 0/101 (0%) | 90/101 (89.1%) |
| RSV60_dTpa_RSV120(Pooled) | 0/103 (0%) | 0/103 (0%) | 91/103 (88.3%) |
| RSV60_Placebo_RSV120(Pooled) | 0/102 (0%) | 1/102 (1%) | 82/102 (80.4%) |
| dTpa_Placebo_RSV120(Pooled) | 0/102 (0%) | 0/102 (0%) | 89/102 (87.3%) |
| Event | RSV120_dTpa_RSV120(Pooled) | RSV120_Placebo_RSV120(Pooled) | RSV60_dTpa_RSV120(Pooled) | RSV60_Placebo_RSV120(Pooled) | dTpa_Placebo_RSV120(Pooled) |
|---|---|---|---|---|---|
| Radius fractureInjury, poisoning and procedural complications | 1/101 | 0/101 | 0/103 | 0/102 | 0/102 |
| Ulna fractureInjury, poisoning and procedural complications | 1/101 | 0/101 | 0/103 | 0/102 | 0/102 |
| Wrist fractureInjury, poisoning and procedural complications | 1/101 | 0/101 | 0/103 | 0/102 | 0/102 |
| PyelonephritisInfections and infestations | 0/101 | 0/101 | 0/103 | 1/102 | 0/102 |
| Event | RSV120_dTpa_RSV120(Pooled) | RSV120_Placebo_RSV120(Pooled) | RSV60_dTpa_RSV120(Pooled) | RSV60_Placebo_RSV120(Pooled) | dTpa_Placebo_RSV120(Pooled) |
|---|---|---|---|---|---|
| Injection site pain - Extension StudyGeneral disorders | 34/39 | 36/41 | 37/46 | 35/41 | 18/46 |
| Injection site pain - Primary StudyGeneral disorders | 86/101 | 62/101 | 84/103 | 60/102 | 81/102 |
| Headache - Extension StudyNervous system disorders | 11/39 | 15/41 | 15/46 | 23/41 | 16/46 |
| Headache - Primary StudyNervous system disorders | 47/101 | 47/101 | 38/103 | 42/102 | 37/102 |
| Fatigue - Extension StudyGeneral disorders | 10/39 | 15/41 | 17/46 | 19/41 | 16/46 |
| Fatigue - Primary StudyGeneral disorders | 42/101 | 40/101 | 39/103 | 34/102 | 38/102 |
| Gastrointestinal disorder - Primary StudyGastrointestinal disorders | 24/101 | 29/101 | 28/103 | 29/102 | 28/102 |
| Gastrointestinal disorder - Extension StudyGastrointestinal disorders | 4/39 | 10/41 | 7/46 | 10/41 | 7/46 |
| Injection site erythema - Extension StudyGeneral disorders | 7/39 | 4/41 | 4/46 | 6/41 | 1/46 |
| Injection site swelling - Extension StudyGeneral disorders | 5/39 | 3/41 | 4/46 | 2/41 | 1/46 |
| Age, Customized(Years) | RSV120_dTpa_RSV120(Pooled) | RSV120_Placebo_RSV120(Pooled) | RSV60_dTpa_RSV120(Pooled) | RSV60_Placebo_RSV120(Pooled) | dTpa_Placebo_RSV120(Pooled) | Total |
|---|---|---|---|---|---|---|
| Mean | 31.4 ± 7.6 | 31.0 ± 8.0 | 30.8 ± 8.4 | 30.5 ± 8.3 | 30.4 ± 7.9 | 30.8 ± 8.0 |
| Age, Customized(Years) | RSV120_dTpa_RSV120(Pooled) | RSV120_Placebo_RSV120(Pooled) | RSV60_dTpa_RSV120(Pooled) | RSV60_Placebo_RSV120(Pooled) | dTpa_Placebo_RSV120(Pooled) | Total |
|---|---|---|---|---|---|---|
| Mean | 32.1 ± 7.9 | 31.7 ± 8.4 | 30.4 ± 8.6 | 30.3 ± 8.4 | 32.6 ± 8.2 | 31.4 ± 8.3 |
| Sex/Gender, Customized(Participants) | RSV120_dTpa_RSV120(Pooled) | RSV120_Placebo_RSV120(Pooled) | RSV60_dTpa_RSV120(Pooled) | RSV60_Placebo_RSV120(Pooled) | dTpa_Placebo_RSV120(Pooled) | Total |
|---|---|---|---|---|---|---|
| Female | 101 | 101 | 103 | 102 | 102 | 509 |
| Male | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex/Gender, Customized(Participants) | RSV120_dTpa_RSV120(Pooled) | RSV120_Placebo_RSV120(Pooled) | RSV60_dTpa_RSV120(Pooled) | RSV60_Placebo_RSV120(Pooled) | dTpa_Placebo_RSV120(Pooled) | Total |
|---|---|---|---|---|---|---|
| Female | 39 | 41 | 46 | 41 | 46 | 213 |
| Male | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | RSV120_dTpa_RSV120(Pooled) | RSV120_Placebo_RSV120(Pooled) | RSV60_dTpa_RSV120(Pooled) | RSV60_Placebo_RSV120(Pooled) | dTpa_Placebo_RSV120(Pooled) | Total |
|---|---|---|---|---|---|---|
| AMERICAN INDIAN OR ALASKA NATIVE | 3 | 0 | 1 | 1 | 0 | 5 |
| ASIAN | 1 | 3 | 2 | 4 | 4 | 14 |
| BLACK OR AFRICAN AMERICAN | 4 | 6 | 8 | 3 | 4 | 25 |
| OTHER Not specified | 2 | 2 | 2 | 2 | 3 | 11 |
| WHITE | 91 | 90 | 90 | 92 | 91 | 454 |
| Race/Ethnicity, Customized(Participants) | RSV120_dTpa_RSV120(Pooled) | RSV120_Placebo_RSV120(Pooled) | RSV60_dTpa_RSV120(Pooled) | RSV60_Placebo_RSV120(Pooled) | dTpa_Placebo_RSV120(Pooled) | Total |
|---|---|---|---|---|---|---|
| AMERICAN INDIAN OR ALASKA NATIVE | 1 | 0 | 0 | 0 | 0 | 1 |
| ASIAN | 1 | 0 | 1 | 2 | 0 | 4 |
| BLACK OR AFRICAN AMERICAN | 0 | 0 | 1 | 0 | 1 | 2 |
| OTHER Not specified | 1 | 0 | 2 | 0 | 1 | 4 |
| WHITE | 36 | 41 | 42 | 39 | 44 | 202 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — GSK will assess requests from qualified researchers for anonymized individual patient-level data (IPD) and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk-studyregister.com
Ran from Nov 2019 to primary completion in Feb 2020, 3 months.
Results were first posted in Dec 2022, 2 years 9 months after primary completion. A results delay was requested in Jan 2021.
Of 32 industry-sponsored phase 2 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's 3 months is below that.
Counting every sponsor, half of 37 studies reached it within 11 months; a quarter within 5 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Boostrix
Respiratory Syncytial Virus Infections →